Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2010-10-14 · DEPARTMENT OF JUSTICE · Proposed Rules

Proposed Rules. DEPARTMENT OF JUSTICE

311 words·~1 min read·/register/2010/10/14/2010-25849·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4410-15-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 28, 2010, PCAS-Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403, made application to the Drug Enforcement Administration
(DEA)as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Amphetamine
(1100)II Methamphetamine
(1105)II Methylphenidate
(1724)II Phencyclidine
(7471)II Codeine
(9050)II Diprenorphine
(9058)II Oxycodone
(9143)II Hydromorphone
(9150)II Hydrocodone
(9193)II Methadone
(9250)II Morphine
(9300)II Oxymorphone
(9652)II Fentanyl
(9801)II The company is a contract manufacturer. At the request of the company's customers, it manufactures derivatives of controlled substances in bulk form only. The primary service provided by the company to its customers is the development of the process of manufacturing the derivative. As part of its service to its customers, the company distributes the derivatives of the controlled substances it manufactures to those customers. The company's customers use the newly-created processes and the manufactured derivatives in furtherance of formulation processes and dosage form manufacturing; pre-clinical studies, including toxicological studies; clinical studies supporting investigational Drug Applications; and use in stability studies. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 13, 2010. Dated: October 6, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010-25849 Filed 10-13-10; 8:45 am]
Connectionstraces to 1
Citation graph
cites case law
Proposed Rules
DEPARTMENT OF JUSTICE
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.